Advancing asthma care: The glass is only half full!

作者：Szefler Stanley J^*

来源：Journal of Allergy and Clinical Immunology, 2011, 128(3): 485-494.

DOI：10.1016/j.jaci.2011.07.010

• Asthma
• childhood asthma
• asthma therapy
• asthma statistics
• asthma management
• asthma guidelines
• asthma disease management
• inhaled corticosteroids
• long-acting beta-adrenergic agonists
• leukotriene receptor antagonists
• omalizumab
• asthma surveillance
• asthma mortality
• asthma hospitalizations
• asthma exacerbations
• asthma progression
• personalized medicine
• public health

Over the past 20 years, there has been a concerted effort in the United States to reduce morbidity related to chronic disease, including asthma. Attention was initially directed toward asthma in response to the recognition that asthma mortality was increasing and that the burden of disease was significant. These efforts to address asthma mortality led to many new initiatives to develop clinical practice guidelines, implement the asthma guidelines into clinical practice, conduct research to fill the gaps in the guidelines, and continuously revise the asthma guidelines as more information became available. An assessment of our progress shows significant accomplishments in relation to reducing asthma mortality and hospitalizations. Consequently, we are now at a crossroads in asthma care. Although we have recognized some remarkable accomplishments in reducing asthma mortality and morbidity, the availability of new tools to monitor disease activity, including biomarkers and epigenetic markers, along with information technology systems to monitor asthma control hold some promise in identifying gaps in disease management. These advances should prompt the evolution of new strategies and new treatments to further reduce disease burden. It now becomes imperative to continue a focus on ways to further reduce the burden of asthma and prevent its onset. (J Allergy Clin Immunol 2011;128:485-94.)

• 出版日期2011-9